Claims
- 1. A method for inhibiting viral replication or infection, comprising contacting a composition comprising a virally infected cell with a substantially cell-impermeant phosphatidylethanolamine (PE) binding peptide, which comprises a PE-binding peptide operatively attached to a cell impermeant group, in an amount effective to inhibit viral replication or infection.
- 2. The method of claim 1, wherein said PE-binding peptide is a lantibiotic peptide.
- 3. The method of claim 2, wherein said PE-binding peptide is a cinnamycin peptide.
- 4. The method of claim 2, wherein said PE-binding peptide is a duramycin peptide.
- 5. The method of claim 1, wherein said PE-binding peptide is operatively attached to a group that has a positive charge at physiological pH.
- 6. The method of claim 1, wherein said PE-binding peptide is operatively attached to a group that has a negative charge at physiological pH.
- 7. The method of claim 1, wherein said PE-binding peptide is operatively attached to a sulfate, sulfonate, phosphate, carboxyl, phenolic, quaternary ammonium ion or amine group.
- 8. The method of claim 1, wherein said PE-binding peptide is operatively attached to biotin.
- 9. The method of claim 1, wherein said PE-binding peptide is operatively attached to a sugar, oligo- or polysaccharide, amino acid, peptide, polypeptide or a polyalcohol group.
- 10. The method of claim 1, wherein said PE-binding peptide is operatively attached to an inert carrier protein.
- 11. The method of claim 10, wherein PE-binding peptide is operatively attached to neutravidin, streptavidin, albumin or an immunoglobulin carrier protein.
- 12. The method of claim 11, wherein PE-binding peptide is operatively attached to a human IgG carrier protein.
- 13. The method of claim 1, wherein said virally infected cell is a mammalian cell.
- 14. The method of claim 1, wherein said virally infected cell is infected with a hepatitis, influenza, HIV, herpes, paramyxovirus or arenavirus.
- 15. The method of claim 1, wherein said method inhibits viral replication in said virally infected cell.
- 16. The method of claim 1, wherein said method inhibits viral spread from said virally infected cell.
- 17. The method of claim 1, wherein said virally infected cell is located within an animal and said substantially cell-impermeant PE-binding peptide is administered to said animal.
- 18. The method of claim 17, wherein said animal is a human patient.
- 19. A method for treating an animal with a viral infection, comprising administering to said animal a pharmaceutical composition comprising a substantially cell-impermeant PE-binding peptide, which comprises a PE-binding peptide operatively attached to a cell impermeant group, in an amount effective to inhibit viral replication or spread in said animal, thereby treating said viral infection.
- 20. The method of claim 19, wherein said pharmaceutical composition is administered to said animal intravenously.
- 21. The method of claim 19, wherein said pharmaceutical composition is administered to said animal as an aerosol.
- 22. The method of claim 19, wherein said animal has, or is at risk for developing, hepatitis, influenza, AIDS, viral pneumonia or respiratory disease or Lassa fever.
- 23. The method of claim 19, wherein at least a second, distinct anti-viral agent is administered to said animal.
- 24. The method of claim 23, wherein said at least a second, distinct anti-viral agent is an anti-viral agent from Table G.
- 25. The method of claim 19, wherein said animal is a human patient.
Parent Case Info
[0001] The present application claims priority to co-pending U.S. application Ser. No. 10/621,269, filed Jul. 15, 2003, which claims priority to U.S. provisional application Ser. No. 60/396,263, filed Jul. 15, 2002, the disclosures of which applications, including the specification, claims, drawings and sequences, are specifically incorporated herein by reference without disclaimer.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60396263 |
Jul 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10621269 |
Jul 2003 |
US |
Child |
10642117 |
Aug 2003 |
US |